MedTrace Logo

Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer

NCT03327883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2021-07-09

No results posted yet for this study

Summary

Background:

Bladder cancer is a common cancer in the U.S. Survival rates for metastatic bladder cancer have not gotten better for 15 years. Diagnosing and assessing the disease is important for treating it. The best way to tell what stage a cancer is in is computed tomography. This is also called CT. But it does not always give the best images of the bladder. Adding a test called positron emission tomography (PET) can help. Magnetic resonance imaging (MRI) is even better than CT for detecting bladder cancer. But it is not widely used.

Some people with bladder cancer have already had MRI/PET and CT. Researchers want to study their records. They want to compare the different ways of assessing the disease.

Objective:

To evaluate the use of MRI/PET for diagnosing and treating metastatic bladder cancer.

Eligibility:

People 18 years and older who were in studies between 2013 and 2016

Design:

Researchers will study existing records. There will be no active participants.

The records will have no data that could identify the participants. Data will be stored on secure computers.

No study participants will be contacted without approval from a review board.

Conditions

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Andrea B Apolo, M.D. · National Cancer Institute (NCI)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-26
Primary Completion
2018-02-15
Completion
2018-10-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03327883 on ClinicalTrials.gov